TY - JOUR
AB - Reactions 1182 - 15 Dec 2007 Risk-minimisation measures implemented for dosulepin The UK MHRA advises that use of dosulepin in new patients should be avoided. Where necessary, only specialist-care prescribers should start treatment in dosulepin-naive patients and they should limit the amount issued per prescription. These measures reflect the small margin of safety between the maximum therapeutic dose of dosulepin and potentially fatal overdoses. In a further move to reduce the risk of fatal overdose, dosulepin has been available in child-resistant blister packs only since November 2007 and pack sizes have been limited. Although the clinical guideline of management of depression jointly developed by the UK NICE and the National Collaborating Centre for Mental Health deems dosulepin as a "less-appropriate treatment", the tricyclic antidepressant continues to be prescribed widely and comprises around 10% of the antidepressant market in England. Dosulepin: measures to reduce risk of fatal overdose. Drug Safety Update 1: 7-8, No. 5, Dec 2007 801052418 0114-9954/10/1182-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved Reactions 15 Dec 2007 No. 1182 
TI - Risk-minimisation measures implemented for dosulepin
JF - Reactions Weekly
DO - 10.2165/00128415-200711820-00002
DA - 2013-01-20
UR - https://www.deepdyve.com/lp/springer-journals/risk-minimisation-measures-implemented-for-dosulepin-9jwZoKZTE1
SP - 2
EP - 2
VL - 1182
IS - 1
DP - DeepDyve
ER -